49% of Clinical Trial Disruption due to Slow Enrollment

As of November 30 2020 the top reason for disrupted clinical trials is slow enrollment which is causing delays in 49% of trials. The other main reasons for disruptions are enrollment suspension at 35% and delayed initiation at 16% says GlobalData a leading data and analytics company.

Scotty Chung-Siu Pharma Analyst at GlobalData comments: “Although suspended trials have begun to recruit participants delays in trial initiation and slow recruitment continue.”

Since June 1 there has been a slow but progressive decline in the number of clinical trial disruptions. The fastest rate of trial disruption was between early April and mid-May and the number of trials disrupted by COVID-19 peaked in the first week of June.

Chung-Siu concludes: “New vaccines that are being approved for the treatment of COVID-19 provide hope that this will change the dynamic of the global pandemic and decrease the number of disrupted clinical trials in the near future.”

Latest Press Release on Clinical Trials News

Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

SHANGHAI , April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time) , Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment f...

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease

Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed i...

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to...

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China , March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: ...

myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials

Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible trea...